Literature DB >> 2825351

Activation of the HIV-1 LTR by T cell mitogens and the trans-activator protein of HTLV-I.

M Siekevitz1, S F Josephs, M Dukovich, N Peffer, F Wong-Staal, W C Greene.   

Abstract

To investigate the mechanism by which immune activation augments replication of the human immunodeficiency virus type 1 (HIV-1) in infected T cells, four different classes of T cell mitogens were evaluated for their effects on the HIV-1 long terminal repeat (LTR). Phytohemagglutinin (PHA), a mitogenic lectin; phorbol 12-myristic 13-acetate, a tumor promoter; ionomycin, a calcium ionophore; and tat-1, the trans-activator protein from the human T cell leukemia/lymphoma virus type I (HTLV-I) each stimulated the HIV-1 LTR. Studies of deleted forms of the LTR supported a central role in these responses for the HIV-1 enhancer, which alone was sufficient for mitogen inducibility, but also suggested that other 5' positive and negative regulatory elements contribute to the overall magnitude of the response. Synergistic activation of the HIV-1 LTR (up to several thousandfold) was observed with combinations of these mitogens and the HIV-1--derived tat-III protein. Cyclosporin A, an immunosuppressive agent, inhibited PHA-mediated activation of the HIV-1 LTR but was without effect in the presence of other mitogens. Thus, HIV-1 gene expression and replication appear to be regulated, via the HIV-1 LTR, by the same mitogenic signals that induce T cell activation.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2825351     DOI: 10.1126/science.2825351

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  182 in total

Review 1.  A compilation of cellular transcription factor interactions with the HIV-1 LTR promoter.

Authors:  L A Pereira; K Bentley; A Peeters; M J Churchill; N J Deacon
Journal:  Nucleic Acids Res       Date:  2000-02-01       Impact factor: 16.971

2.  Reservoirs for HIV-1.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-08       Impact factor: 3.725

3.  Human T-cell leukemia virus type 1 Tax protein binds to assembled nuclear proteasomes and enhances their proteolytic activity.

Authors:  J Hemelaar; F Bex; B Booth; V Cerundolo; A McMichael; S Daenke
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

4.  The v-rel oncogene: insights into the mechanism of transcriptional activation, repression, and transformation.

Authors:  W H Walker; B Stein; P A Ganchi; J A Hoffman; P A Kaufman; D W Ballard; M Hannink; W C Greene
Journal:  J Virol       Date:  1992-08       Impact factor: 5.103

Review 5.  Mechanism of action of regulatory proteins encoded by complex retroviruses.

Authors:  B R Cullen
Journal:  Microbiol Rev       Date:  1992-09

6.  Early transcription from nonintegrated DNA in human immunodeficiency virus infection.

Authors:  Yuntao Wu; Jon W Marsh
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

7.  Human T-cell lymphotropic virus type 1 p12I enhances interleukin-2 production during T-cell activation.

Authors:  Wei Ding; Seung-Jae Kim; Amrithraj M Nair; Bindhu Michael; Kathleen Boris-Lawrie; Adam Tripp; Gerold Feuer; Michael D Lairmore
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

8.  Coexpression of NF-kappa B/Rel and Sp1 transcription factors in human immunodeficiency virus 1-induced, dendritic cell-T-cell syncytia.

Authors:  A Granelli-Piperno; M Pope; K Inaba; R M Steinman
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-21       Impact factor: 11.205

9.  Selective infection of human T-lymphotropic virus type 1 (HTLV-1)-infected cells by chimeric human immunodeficiency viruses containing HTLV-1 tax response elements in the long terminal repeat.

Authors:  H C Lin; M Bodkin; R B Lal; A B Rabson
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

10.  Identification of cellular proteins that bind to the human immunodeficiency virus type 1 trans-activation-responsive TAR element RNA.

Authors:  A Gatignol; A Kumar; A Rabson; K T Jeang
Journal:  Proc Natl Acad Sci U S A       Date:  1989-10       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.